Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 4
Submit an article Journal homepage
191
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy

Sara Harryssona Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;b Department of Hematology, Karolinska University Hospital, Solna, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4955-4728View further author information
ORCID Icon,
Sandra Elorantaa Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, SwedenView further author information
,
Sara Ekberga Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, SwedenView further author information
,
Gunilla Enbladc Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenView further author information
,
Per-Ola Anderssond Department of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, and Sahlgrenska Academy, Gothenburg University, Gothenburg, SwedenView further author information
,
Kristina Sonnevib Department of Hematology, Karolinska University Hospital, Solna, SwedenView further author information
,
Maria Ljungqvista Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;b Department of Hematology, Karolinska University Hospital, Solna, SwedenView further author information
,
Birgitta Sandere Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;e Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SwedenView further author information
,
Mats Jerkemanf Department of Oncology, Lund University, Lund, SwedenView further author information
&
Karin E. Smedbya Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;b Department of Hematology, Karolinska University Hospital, Solna, SwedenView further author information
 show all
Pages 534-537 | Received 21 Sep 2023, Accepted 12 Dec 2023, Published online: 22 Dec 2023

References

  • El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57–68. doi:10.1016/j.ejca.2018.01.073
  • Patrij K, Reiser M, Wätzel L, et al. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis. Ger Med Sci. 2011;9:doc11. doi:10.3205/000134
  • Ferreri AJ, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients With systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–3910. doi:10.1200/jco.2015.61.1236
  • Cheah CY, Joske D, Cull G, et al. High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. Br J Haematol. 2017;178(6):991–994. doi:10.1111/bjh.14187
  • Ferreri AJM, Doorduijn JK, Re A, et al. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021;8(2):e110–e121. doi:10.1016/s2352-3026(20)30366-5
  • Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013;98(3):364–370. doi:10.3324/haematol.2012.077917
  • Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980
  • Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
  • Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2021;386(7):629–639. doi:10.1056/NEJMoa2116596
  • Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi:10.1056/NEJMoa2116133
  • Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. doi:10.1016/s0140-6736(22)00662-6
  • Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood. 2019;134(11):860–866. doi:10.1182/blood.2019001694
  • Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021;5(24):5626–5630. doi:10.1182/bloodadvances.2021005292
  • Harrysson S, Eloranta S, Ekberg S, et al. Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer J. 2021;11(1):9. doi:10.1038/s41408-020-00403-1
  • Harrysson S, Eloranta S, Ekberg S, et al. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-a population-based study of 736 patients. Br J Haematol. 2022;198(2):267–277. doi:10.1111/bjh.18197

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.